|
US2004115217A1
|
|
Bystander suppression of autoimmune diseases
|
|
AU2256900A
|
|
Method of treating rheumatoid arthritis with low dose type II collagen
|
|
AU2868699A
|
|
Treatment of multiple sclerosis using cop-1 and th2-enhancing cytokines
|
|
EP0994717A1
|
|
Treatment of autoimmune disease using tolerization in combination with methotrexate
|
|
US5935577A
|
|
Treatment of autoimmune disease using tolerization in combination with methotrexate
|
|
HU9901821A2
|
|
Method for preparation of type ii collagen
|
|
BR9610625A
|
|
Pharmaceutical composition to suppress a peptide immune response and method for preparing a pharmaceutical composition
|
|
US5856446A
|
|
Method of treating rheumatoid arthritis with low dose type II collagen
|
|
IL122502D0
|
|
Medicaments for inducing oral tolerance in skin diseases presenting with t-cell mediated inflammation
|
|
US5641474A
|
|
Prevention of autoimmune diseases by aerosol administration of autoantigens
|
|
US5571500A
|
|
Treatment of autoimmune diseases through administration by inhalation of autoantigens
|
|
US5858980A
|
|
Peptide fragments of myelin basic protein
|
|
US5571499A
|
|
Treatment of autoimmune diseases by aerosol administration of autoantigens
|
|
US6645504B1
|
|
Bystander suppression of type I diabetes by oral administration of glucagon
|
|
US5869054A
|
|
Treatment of multiple sclerosis by oral administration of autoantigens
|
|
US5645820A
|
|
Treatment of autoimmune diseases by aerosol administration of autoantigens
|
|
IL110899D0
|
|
Method of treating rheumatoid arthritis with type II collagen
|
|
US6039947A
|
|
Peptides derived from immunodominant epitopes of myelin basic protein
|
|
IL109188D0
|
|
Suppression of t-cell proliferation using peptide fragments of myelin basic protein
|
|
EP0662838A1
|
|
Method of treating rheumatoid arthritis with type ii collagen.
|
